SCHEMBL18996019

SCHEMBL18996019

Cc1ccc(NC(=O)NC(=O)CSc2nc3ccccc3nc2C)cc1

nearest known ligand 0.86

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NEDD4 P46934 1/20 0.86
PKM P14618 1/20 0.57
LMNA P02545 4/20 0.56
MAPT P10636 5/20 0.54
ALDH1A1 P00352 2/20 0.53
SMN1; SMN2 Q16637 2/20 0.53
MAPK1 P28482 1/20 0.53
HTT P42858 1/20 0.53
MPO P05164 1/20 0.51
MEN1 O00255 1/20 0.50
KMT2A Q03164 1/20 0.50
RXFP1 Q9HBX9 4/20 0.49
TP53 P04637 3/20 0.46
THRB P10828 1/20 0.46
KDM4E B2RXH2 1/20 0.46
NPC1 O15118 1/20 0.46
ADRB2 P07550 1/20 0.46
RAB9A P51151 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17141990 0.93 NEDD4 (1.00) NEDD4PKMLMNAMAPTALDH1A1
SCHEMBL17141988 0.91 NEDD4 (0.83) NEDD4PKMLMNAMAPTALDH1A1
SCHEMBL18996018 0.87 NEDD4 (0.81) NEDD4LMNAMAPTALDH1A1SMN1; SMN2
SCHEMBL18996017 0.85 LMNA (0.73) NEDD4LMNAMAPTRXFP1TP53
SCHEMBL17141933 0.84 NEDD4 (0.79) NEDD4PKMLMNAMAPTALDH1A1
SCHEMBL17141961 0.83 NEDD4 (0.78) NEDD4PKMLMNAMAPTALDH1A1
SCHEMBL17141981 0.82 NEDD4 (0.76) NEDD4PKMLMNAMAPTALDH1A1
SCHEMBL17142013 0.82 NEDD4 (0.69) NEDD4PKMLMNAMAPTALDH1A1
SCHEMBL17141916 0.81 NEDD4 (0.72) NEDD4LMNAMAPTALDH1A1SMN1; SMN2
SCHEMBL17141919 0.81 NEDD4 (0.71) NEDD4LMNAMAPTALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170174678-A1 NOVEL ANTIVIRAL COMPOUNDS AND METHODS USING SAME Rhe Trustees of The University of Pennsylvania 2017-06-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170174678-A1 NOVEL ANTIVIRAL COMPOUNDS AND METHODS USING SAME ZC3HAV1, MAVS, ZC3HAV1L NEDD4 2641/4885PKM 3984/4885LMNA 2215/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.